← All trials
NCT01217723
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2010
- Primary completion
- Jan 1, 2014
- Completion date
- Jan 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 198
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- McMaster UniversityLead sponsor
- McMaster UniversityStudy chair
- GenzymeCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- The Canadian Blood and Marrow Transplant GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.